Last reviewed · How we verify
Human immunodeficiency virus I infection
Approved treatments
- Rukobia · GSK
Rukobia works by blocking the potassium voltage-gated channel subfamily H member 2, which is involved in the replication of the human immunodeficiency virus 1. - Vocabria · GSK
Vocabria works by blocking the integrase enzyme, which is necessary for the virus to replicate.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Human immunodeficiency virus I infection patent landscape — cliff calendar, originator estates, attackable patents
- Human immunodeficiency virus I infection treatment landscape brief
- Human immunodeficiency virus I infection treatment updates RSS
Frequently asked questions about Human immunodeficiency virus I infection
What drugs treat Human immunodeficiency virus I infection?
Tracked treatments include Rukobia, Vocabria.
What is the treatment for Human immunodeficiency virus I infection?
Standard treatment for Human immunodeficiency virus I infection includes Rukobia, Vocabria. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Human immunodeficiency virus I infection patent cliff · Human immunodeficiency virus I infection CI report
- Treatment: Rukobia · GSK
- Treatment: Vocabria · GSK
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing